First in new class of migraine prophylactics launched

Erenumab (Aimovig) belongs to a new class of migraine prophylactics known as calcitonin gene-related peptide (CGRP) antagonists and is injected once monthly.

by Lisa Lytle
Around 10 million UK adults (aged 15-69) are thought to experience migraine, with more than 190,000 migraine attacks estimated to occur every day. | DR. G. RAVILY/SCIENCE PHOTO LIBRARY
Around 10 million UK adults (aged 15-69) are thought to experience migraine, with more than 190,000 migraine attacks estimated to occur every day. | DR. G. RAVILY/SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package